Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 1

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 1
---
 of WallachBeth. See “Selling Stockholders” beginning on page 41 of this prospectus for more information
about the Selling Stockholders. The registration of the shares of Common Stock to which this prospectus relates does not require the Selling
Stockholders to sell any of their shares of our Common Stock.

We are not offering any shares of Common Stock under
this prospectus and will not receive any proceeds from the sale or other disposition of the shares of our Common Stock covered hereby.
However, we will receive the proceeds from any exercise of the Common Warrants for cash. See “Use of Proceeds” beginning on
page 38 of this prospectus.

The Selling Stockholders identified in this prospectus,
or their pledgees, assignees, donees, transferees or their respective successors-in-interest, from time to time may offer and sell through
public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices
the shares held by them directly or through underwriters, agents or broker-dealers on terms to be determined at the time of sale, as described
in more detail in this prospectus. See “Plan of Distribution” beginning on page 83 of this prospectus for more information
about how the Selling Stockholders may sell their respective shares of Common Stock. The Selling Stockholders may be deemed “underwriters”
within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended.

We have agreed to bear all of the expenses in connection
with the registration of the Common Warrant Shares pursuant to this prospectus. The Selling Stockholders will pay or assume all commissions,
discounts, fees of underwriters, agents, selling brokers or dealer managers and similar expenses, if any, attributable to their respective
sales of the shares of Common Stock.

Our Common Stock is listed on the Nasdaq Capital
Market under the symbol “BIAF”. Our Tradeable Warrants are listed on the Nasdaq Capital Market under the symbol “BIAFW”.
On April 17, 2025, the last reported sale price of (i) our Common Stock on Nasdaq was $0.515 per share, and (ii) our Tradeable
Warrants on Nasdaq was $0.2667 per Tradeable Warrant. There is no established public trading market for any of the Common Warrants
and we do not expect a market to develop.

Investing in our securities involves risks. You should